{"id":"nesiritide-furosemide","safety":{"commonSideEffects":[{"rate":"7-11%","effect":"Hypotension"},{"rate":"8-9%","effect":"Headache"},{"rate":"5-7%","effect":"Dizziness"},{"rate":"4-5%","effect":"Nausea"},{"rate":"2-3%","effect":"Abdominal pain"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Worsening renal function"}]},"_chembl":{"chemblId":"CHEMBL1201668","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nesiritide binds to natriuretic peptide receptors on vascular smooth muscle and endothelial cells, causing vasodilation and reducing cardiac preload and afterload. Furosemide blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, promoting diuresis and reducing fluid overload. Together, they work synergistically to reduce pulmonary and systemic congestion in acute decompensated heart failure.","oneSentence":"Nesiritide is a recombinant B-type natriuretic peptide that promotes vasodilation and sodium excretion, while furosemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending loop of Henle.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:58.877Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute decompensated heart failure with dyspnea at rest or with minimal exertion"}]},"trialDetails":[{"nctId":"NCT01584518","phase":"NA","title":"B-type Natriuretic Peptide as a Surrogate Marker Guiding Post-operative Fluid Off-loading","status":"COMPLETED","sponsor":"Creighton University","startDate":"2012-07","conditions":"Fluid Over-load","enrollment":50},{"nctId":"NCT00806910","phase":"PHASE4","title":"Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion","status":"WITHDRAWN","sponsor":"Albert Einstein Healthcare Network","startDate":"2008-10","conditions":"Heart Failure","enrollment":""},{"nctId":"NCT00652652","phase":"PHASE4","title":"Evaluation of Combined Action Between Natrecor and Furosemide on Kidney and Neurohormone Responses in Chronic Heart Failure: A Phase-IV study704.351 / DSS","status":"COMPLETED","sponsor":"Scios, Inc.","startDate":"2003-03","conditions":"Congestive Heart Failure, Chronic Heart Failure","enrollment":""},{"nctId":"NCT00473148","phase":"PHASE3","title":"B-type Natriuretic Peptide for the Management of Weaning","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-06","conditions":"Respiratory Insufficiency","enrollment":265}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":175,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"nesiritide, furosemide","genericName":"nesiritide, furosemide","companyName":"Scios, Inc.","companyId":"scios-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nesiritide is a recombinant B-type natriuretic peptide that promotes vasodilation and sodium excretion, while furosemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending loop of Henle. Used for Acute decompensated heart failure with dyspnea at rest or with minimal exertion.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}